Related Experiment Video
Updated: Jun 12, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Cost effectiveness of a general practice chronic disease management plan for coronary heart disease in Australia
Derek P Chew1, Robert Carter, Bree Rankin
1Flinders Medical Centre, Flinders University, Flinders Drive, Bedford Park, SA 5042, Australia. derek.chew@flinders.edu.au
Insights
A new Australian program for coronary heart disease (CHD) management in general practice is likely cost-effective. This approach optimizes current therapies, offering substantial benefits to the community.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Preventive Cardiology
Background:
- The cost-effectiveness of general practice-based coronary heart disease (CHD) management programs in Australia is not well-established.
- Existing management strategies for CHD patients require economic evaluation within the Australian healthcare context.
Purpose of the Study:
- To evaluate the economic viability of a secondary prevention program for CHD patients managed in Australian general practice.
- To determine the incremental cost-effectiveness ratio (ICER) of an optimized CHD management program.
Main Methods:
- An economic model was developed to assess a secondary prevention program.
- The program involved clinical assessment, pharmacotherapy optimization, lifestyle modification, a disease registry, and financial incentives.
- Cost-effectiveness was measured using the ICER in Australian dollars per disability-adjusted life year (DALY) prevented.
Main Results:
- In 2006, CHD accounted for 263,487 DALYs in Australia.
- The proposed program estimated an annual cost of $115,650,000.
- With a 15% reduction in mortality/disability and 40% uptake, the ICER was $8081 per DALY prevented; sensitivity analysis yielded up to $38,316 per DALY.
Conclusions:
- Current CHD therapies offer proven benefits for reducing morbidity and mortality.
- A general practice-based program effectively applying these therapies is likely cost-effective.
- Such a program promises significant and sustainable advantages for the Australian community.
Background:
The cost effectiveness of a general practice-based program for managing coronary heart disease (CHD) patients in Australia remains uncertain. We have explored this through an economic model.
Methods:
A secondary prevention program based on initial clinical assessment and 3 monthly review, optimising of pharmacotherapies and lifestyle modification, supported by a disease registry and financial incentives for quality of care and outcomes achieved was assessed in terms of incremental cost effectiveness ratio (ICER), in Australian dollars per disability adjusted life year (DALY) prevented.
Results:
Based on 2006 estimates, 263 487 DALYs were attributable to CHD in Australia. The proposed program would add $115 650 000 to the annual national heath expenditure. Using an estimated 15% reduction in death and disability and a 40% estimated program uptake, the program's ICER is $8081 per DALY prevented. With more conservative estimates of effectiveness and uptake, estimates of up to $38 316 per DALY are observed in sensitivity analysis.
Conclusions:
Although innovation in CHD management promises improved future patient outcomes, many therapies and strategies proven to reduce morbidity and mortality are available today. A general practice-based program for the optimal application of current therapies is likely to be cost-effective and provide substantial and sustainable benefits to the Australian community.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome IV: Interprofessional Care
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Rheumatic Heart Disease III: Medical Management